Serum erythropoietin in hepatocellular carcinoma.

被引:0
|
作者
Malaguarnera, M [1 ]
Bentivegna, P [1 ]
DiFazio, I [1 ]
Laurino, A [1 ]
Romano, M [1 ]
Trovato, BA [1 ]
机构
[1] UNIV ETUD CATANIA, DEPT MED INTERNE & GERIATR, CATANIA, ITALY
关键词
erythropoietin; hepatocellular carcinoma; anemia;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hemopoietic alterations may occur during tumoral diseases, determining anemia. In most cases, serum EPO levels were lower than normal values. Hepatocellular carcinoma (HCC), one of the most frequent malignancies world-wide, is often characterized by mild anemia and increased serum EPO levels. We studied 30 HCC patients and 20 healthy subjects. We found that HCC patients presented higher serum EPO levels than healthy controls. In HCC patients, there was a significant inverse correlation between serum EPO levels and red blood cell count or hemoglobin levels. We postulated that the elevated serum EPO levels observed in these patients may be due to reduced hepatic clearance of EPO, and to the influence of cytokine-mediated inflammatory factors.
引用
收藏
页码:977 / 980
页数:4
相关论文
共 50 条
  • [21] Genetic alterations in hepatocellular carcinoma.
    Boige, V
    LaurentPuig, P
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (01): : 34 - 44
  • [22] Heterogeneity of pediatric hepatocellular carcinoma.
    D'Souza, Amber M.
    Towbin, Alexander
    Bondoc, Alexander
    Gupta, Anita
    Nathan, Jaimie
    Alonso, Maria
    Tiao, Greg
    Geller, James I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Telomerase,activity in hepatocellular carcinoma.
    Park, SH
    Kwon, SW
    Kim, KS
    Chae, KJ
    Oh, BK
    Park, YN
    Choi, JS
    Lee, WJ
    Park, C
    Kim, BR
    [J]. HEPATOLOGY, 2002, 36 (04) : 447A - 447A
  • [24] Gene therapy of hepatocellular carcinoma.
    王学浩
    李国强
    [J]. 中华肝脏病杂志, 2004, (11) : 56 - 57
  • [25] Hepatocellular carcinoma. Therapeutic perspectives
    Mohr, L.
    [J]. GASTROENTEROLOGE, 2007, 2 (01): : 34 - 39
  • [26] Surgical treatment of hepatocellular carcinoma.
    Cherqui, D
    [J]. ANNALES DE CHIRURGIE, 1998, 52 (01): : 79 - 81
  • [27] Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.
    Zakka, Katerina Mary
    Jiang, Renjian
    Alese, Olatunji B.
    Shaib, Walid Labib
    Wu, Christina
    Wedd, Joel
    Sellers, Marty T.
    Behera, Madhusmita
    El-Rayes, Bassel F.
    Akce, Mehmet
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] NOVEL SERUM BIOMARKERS USEFUL FOR DRUG SELECTION OF SORAFENIB AND LENVATINIB FOR HEPATOCELLULAR CARCINOMA.
    Narahara, Satoshi
    Watanabe, Takehisa
    Tanaka, Kentaro
    Inada, Hiroki
    Kurano, Sotaro
    Tokunaga, Takayuki
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Setoyama, Hiroko
    Tateyama, Masakuni
    Tanaka, Yasuhito
    [J]. HEPATOLOGY, 2021, 74 : 658A - 659A
  • [29] Prognostic role of serum vascular endothelial growth factor level in hepatocellular carcinoma.
    Tan, A.
    Aucejo, F.
    Liu, X.
    Lopez, R.
    Kim, R. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Carbohydrate-deficient transferrin serum values as an early marker of hepatocellular carcinoma.
    Stefanini, GE
    Olanda, S
    Foschi, FG
    Marsigli, L
    Biselli, M
    Castelli, E
    Capelli, M
    Lizzani, L
    Bernardi, M
    Gasbarrini, G
    [J]. HEPATOLOGY, 1997, 26 (04) : 170 - 170